BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6697813)

  • 1. Combination of anticancer agents with folic acid in the treatment of murine leukaemia P388.
    Parchure M; Ambaye RY; Gokhale SV
    Chemotherapy; 1984; 30(2):119-24. PubMed ID: 6697813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of combination chemotherapy of MCNU with various anti-cancer agents].
    Machida S; Ito Y; Hoshino A
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):298-302. PubMed ID: 3918506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of vincristine by vitamin A against drug-resistant mouse leukaemia cells.
    Nogae I; Kikuchi J; Yamaguchi T; Nakagawa M; Shiraishi N; Kuwano M
    Br J Cancer; 1987 Sep; 56(3):267-72. PubMed ID: 3663474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy of early and advanced murine P388 leukaemia with bouvardin, cis-diamminedichloroplatinum and vincristine.
    Adwankar MK; Khandalekar DD; Chitnis MP
    Oncology; 1984; 41(5):370-3. PubMed ID: 6540853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation by vitamin A of the action of anticancer agents against murine tumors.
    Nakagawa M; Yamaguchi T; Ueda H; Shiraishi N; Komiyama S; Akiyama S; Ogata J; Kuwano M
    Jpn J Cancer Res; 1985 Sep; 76(9):887-94. PubMed ID: 3932288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experimental combination chemotherapy of YNK01, a novel analog of cytarabine, with other antitumor agents].
    Uchida T; Nagahata T; Arakawa M; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1990 Jul; 17(7):1351-6. PubMed ID: 2114829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukaemia in mice.
    Kiue A; Sano T; Naito A; Okumura M; Kohno K; Kuwano M
    Br J Cancer; 1991 Aug; 64(2):221-6. PubMed ID: 1892749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Treat Rep; 1985 May; 69(5):523-5. PubMed ID: 4005874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
    Harrison SD; O'Dwyer PJ; Trader MW
    Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of bromovinyldeoxyuridine and fractionated or continuous administration of 5-fluorouracil in P388 leukemia-bearing mice.
    Keizer HJ; Pauwels R; Landuyt W; Balzarini J; van der Schueren E; De Clercq E
    Cancer Lett; 1988 Mar; 39(2):217-23. PubMed ID: 3359416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52.
    Shinoda H; Inaba M; Tsuruo T
    Cancer Res; 1989 Apr; 49(7):1722-6. PubMed ID: 2924316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of in vivo development of resistance to various classes of antitumor agents in P388 leukemia.
    Inaba M; Fujikura R; Sakurai Y
    Gan; 1979 Oct; 70(5):607-13. PubMed ID: 520752
    [No Abstract]   [Full Text] [Related]  

  • 13. Experimental combination chemotherapy of pirarubicin with various antitumor drugs against P388 murine leukemia.
    Izumi H; Hirano S; Matsushita Y; Iguchi H; Tone H; Takeuchi T
    Cancer Biochem Biophys; 1994 Sep; 14(2):137-49. PubMed ID: 7889494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia.
    Leopold WR; Dykes DJ; Griswold DP
    NCI Monogr; 1987; (5):99-104. PubMed ID: 2963231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined effect of CDDP with various types of antitumor drugs against P 388 leukemia].
    Uchida T; Nishikawa K; Shibasaki C; Okamoto K; Arakawa M; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2275-82. PubMed ID: 2735770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of the in vivo P388 leukemia model in evaluation of antitumor activity of natural products.
    Marsh JC; Shoemaker RH; Suffness M
    Cancer Treat Rep; 1985 Jun; 69(6):683-5. PubMed ID: 4016772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro.
    Kiue A; Sano T; Naito A; Inada H; Suzuki K; Okumura M; Kikuchi J; Sato S; Takano H; Kohno K
    Jpn J Cancer Res; 1990 Oct; 81(10):1057-64. PubMed ID: 1977728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia.
    Warrington RC; Fang WD
    Br J Cancer; 1989 Nov; 60(5):652-6. PubMed ID: 2803940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combined use of anticancer drugs with a polysaccharide preparation, Krestin, on mouse leukemia P388.
    Oh-hashi F; Kataoka T; Tsukagoshi S
    Gan; 1978 Apr; 69(2):255-7. PubMed ID: 680463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
    Inaba M; Maruyama E
    Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.